Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 1 for Lonza Guangzhou Pharmaceutical Ltd..
Lonza Guangzhou Pharmaceutical Ltd.: 0 warning letters, 0 recalls, 0 approval records, 1 Form 483.
Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.
Side by side
Lonza Guangzhou Pharmaceutical Ltd. — Warning letters0
Philips North America — Warning letters0
Lonza Guangzhou Pharmaceutical Ltd. — Recalls0
Philips North America — Recalls355
Lonza Guangzhou Pharmaceutical Ltd. — Approval records0
Philips North America — Approval records0
Lonza Guangzhou Pharmaceutical Ltd. — Form 483s1
Philips North America — Form 483s0
Timeline
Cite this comparison
Pre-formatted for a story, footnote, or reference list:
"Lonza Guangzhou Pharmaceutical Ltd. vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed August 29, 2026. https://argushq.ai/compare/lonza-guangzhou-pharmaceutical-ltd-vs-philips-north-america
Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗